Stockreport

ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

ContraFect Corporation  (CFRX) 
Last contrafect corporation earnings: 3/18 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.contrafect.com
PDF YONKERS, N.Y., Dec. 20, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development [Read more]